Dianhydrogalactitol (VAL-083) reduces glioblastoma tumor growth in vivo, upon bevacizumab-induced hypoxia

Anna Golebiewska; Anais Oudin; Anne Steino; Simone Niclou; Dennis Brown; Jeffrey Bacha

doi:10.1093/neuonc/noy148.374

Dianhydrogalactitol (VAL-083) reduces glioblastoma tumor growth in vivo, upon bevacizumab-induced hypoxia

Anna Golebiewska, Anais Oudin, Anne Steino, Simone Niclou, Dennis Brown, Jeffrey Bacha

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	EXTH-25
Pages (from-to)	90-90
Journal	Neuro-Oncology
Volume	20
Issue number	Suppl.6
DOIs	https://doi.org/10.1093/neuonc/noy148.374
Publication status	Published - Nov 2018
Event	23rd Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO) / 3rd CNS Anticancer Drug Discovery and Development Conference - New Orleans, United States Duration: 4 Nov 2018 → 18 Nov 2018

Access to Document

10.1093/neuonc/noy148.374Licence: Unspecified

Cite this

@article{c068d6fe9dbc4b5f9c68c799cbbb07bd,

title = "Dianhydrogalactitol (VAL-083) reduces glioblastoma tumor growth in vivo, upon bevacizumab-induced hypoxia",

author = "Anna Golebiewska and Anais Oudin and Anne Steino and Simone Niclou and Dennis Brown and Jeffrey Bacha",

year = "2018",

month = nov,

doi = "10.1093/neuonc/noy148.374",

language = "English",

volume = "20",

pages = "90--90",

journal = "Neuro-Oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

number = "Suppl.6",

note = "23rd Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO) / 3rd CNS Anticancer Drug Discovery and Development Conference ; Conference date: 04-11-2018 Through 18-11-2018",

}

TY - JOUR

T1 - Dianhydrogalactitol (VAL-083) reduces glioblastoma tumor growth in vivo, upon bevacizumab-induced hypoxia

AU - Golebiewska, Anna

AU - Oudin, Anais

AU - Steino, Anne

AU - Niclou, Simone

AU - Brown, Dennis

AU - Bacha, Jeffrey

PY - 2018/11

Y1 - 2018/11

U2 - 10.1093/neuonc/noy148.374

DO - 10.1093/neuonc/noy148.374

M3 - Meeting Abstract

SN - 1522-8517

VL - 20

SP - 90

EP - 90

JO - Neuro-Oncology

JF - Neuro-Oncology

IS - Suppl.6

M1 - EXTH-25

T2 - 23rd Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO) / 3rd CNS Anticancer Drug Discovery and Development Conference

Y2 - 4 November 2018 through 18 November 2018

ER -